ReviewCardiovascular intervention and therapeutics2026
Residual inflammatory risk after percutaneous coronary intervention: current insights and future perspectives.
Review in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in percutaneous coronary intervention (PCI) and contemporary secondary prevention, recurrent cardiovascular events remain a major clinical challenge. Increasing evidence suggests that persistent vascular inflammation contributes to residual cardiovascular risk after PCI, even in patients receiving optimal lipid-lowering therapy. Recent studies have highlighted the clinical relevance of inflammatory biomarkers, plaque vulnerability, and intracoronary imaging findings in predicting adverse cardiovascular outcomes. In addition, anti-inflammatory therapeutic strategies have emerged as promising approaches for residual risk reduction. This review summarizes current insights into the mechanisms, assessment, and potential therapeutic implications of residual inflammatory risk after PCI.
Indexed as
Identifiers
42337149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.